```html

Ursine Rabies – Comprehensive Medical Guide

Overview

Ursine rabies is a variant of the rabies virus that is primarily maintained in wild bear populations (Ursidae). The virus is a neurotropic lyssavirus that causes acute, progressive encephalitis in both animals and humans. While the classic “dog‑derived” rabies is the most common source of human infection worldwide, occasional spill‑over events from bears have been documented in North America, parts of Europe, and Asia.

Who it affects: Anyone who is bitten, scratched, or has mucous‑membrane exposure to the saliva or neural tissue of an infected bear is at risk. Occupational groups—wildlife biologists, park rangers, hunters, and trappers—are the most frequently exposed. Tourists who engage in close contact with bears (e.g., feeding or handling) also represent a growing at‑risk population.

Prevalence: Bear‑associated rabies is rare. In the United States, the CDC reports fewer than 10 human exposures per decade. In Europe, the European Centre for Disease Prevention and Control (ECDC) notes sporadic cases, mainly in the Balkans and Siberian regions, with an estimated 0.5–1 case per million bear population per year. Despite its rarity, the high fatality rate (≈100 % once clinical signs appear) makes vigilance essential.

Symptoms

The incubation period for ursine rabies ranges from 3 weeks to 3 months, but may be shorter (as little as 7 days) after a deep bite to a highly vascular area. The clinical course can be divided into three phases.

Prodromal Phase (1‑3 days)

• Pain or paresthesia at the bite site – often described as burning, tingling, or numbness.
• Fever – low‑grade (38‑38.5 °C / 100‑101.5 °F).
• General malaise – fatigue, headache, and muscle aches.

Acute Neurologic Phase (2‑10 days)

• Excitability or irritability – patients become anxious, restless, and may have agitation.
• Hydrophobia – fear of water caused by painful throat spasms when attempting to swallow.
• Pharyngolaryngeal spasm – difficulty speaking or swallowing; may sound “hoarse.”
• Hyperventilation & tachypnea – rapid, shallow breathing.
• Autonomic instability – sweating, tachycardia, hypertension, or hypotension.
• Seizures – focal or generalized, occurring in up to 30 % of cases.
• Hallucinations & confusion – delirium leading to disorientation.

Paralytic (Dumb) Phase (optional, 2‑7 days)

• Progressive paralysis – often beginning at the site of the bite and spreading proximally.
• Bulbar dysfunction – loss of gag, cough, and swallow reflexes.
• Respiratory failure – due to diaphragmatic paralysis.

Not all patients experience every symptom; the “furious” form (most common) presents with agitation and hydrophobia, whereas the “paralytic” form may mimic Guillain‑Barré syndrome.

Causes and Risk Factors

Cause

Ursine rabies is caused by infection with the *Rabies lyssavirus* carried by infected bears. The virus replicates in muscle cells at the wound site, then travels retrograde along peripheral nerves to the central nervous system (CNS), where it causes widespread encephalitis.

Risk Factors

• Direct contact with bears – bites, scratches, or exposure of open wounds to bear saliva.
• Geographic exposure – living, working, or traveling in regions with documented bear rabies (e.g., Alaska, Northern Canada, Siberian taiga, Balkan forests).
• Lack of pre‑exposure vaccination – individuals without rabies immunization are far more vulnerable.
• Poor wound care – failure to wash or disinfect a bite within the first hour increases viral load.
• Immunocompromised status – HIV, transplant recipients, or chemotherapy patients may have delayed immune response.

Diagnosis

Because once symptoms appear the disease is almost uniformly fatal, prompt laboratory confirmation is essential for public‑health surveillance and for guiding post‑exposure prophylaxis (PEP) in contacts.

Clinical Diagnosis

• History of bear exposure combined with the characteristic neurological picture.
• Exclusion of other causes of encephalitis (e.g., HSV, West Nile virus).

Laboratory Tests

1. Direct fluorescent antibody (DFA) test – the gold‑standard; performed on skin biopsy from the site of the bite (hair follicles) or on brain tissue (post‑mortem).
2. RT‑PCR – detects viral RNA in saliva, cerebrospinal fluid (CSF), or skin samples; highly sensitive in early disease.
3. Serology – detection of rabies‑specific IgM/IgG in serum or CSF; useful after day 7 of symptom onset.
4. Imaging – MRI may show hyperintensity in the brainstem, hippocampus, or basal ganglia, but findings are non‑specific.

All suspected cases must be reported to local health authorities per CDC and WHO guidelines.

Treatment Options

Once clinical disease is established, there is no proven cure. Management is principally supportive, aimed at keeping the patient comfortable while preventing secondary complications.

Post‑Exposure Prophylaxis (PEP)

• Immediate wound cleansing – flush with >15 L of soap‑water for at least 15 minutes.
• Rabies immunoglobulin (RIG) – 20 IU/kg of human RIG infiltrated around the wound site, if the patient has not been previously vaccinated.
• Active immunization – a 4‑dose series of purified chick embryo cell vaccine (e.g., Imovax® or Rabavert®) on days 0, 3, 7, and 14 (or day 28 for immunocompromised).

Supportive Care for Symptomatic Disease

• Intensive care unit (ICU) monitoring.
• Mechanical ventilation for respiratory failure.
• Control of seizures with benzodiazepines or levetiracetam.
• Management of autonomic instability using beta‑blockers or vasopressors as needed.
• Palliative measures—analgesia, anxiolytics, and humane end‑of‑life care.

Experimental Therapies (investigational)

Milwaukee protocol (induced coma with antiviral agents) has been attempted in a few cases with extremely limited success; it remains controversial and is not recommended as standard care by the WHO or CDC.

Living with Ursine Rabies

Because the disease is fatal once symptomatic, “living with” refers to individuals who have completed pre‑exposure vaccination or who are undergoing post‑exposure prophylaxis after a bite.

• Adhere to the vaccine schedule – missing a dose reduces efficacy; set reminders.
• Monitor the wound – watch for increasing pain, redness, swelling, or discharge; report any changes to a clinician.
• Maintain good nutrition and hydration – supports immune response.
• Limit alcohol and smoking – both impair wound healing and immunity.
• Stay informed – follow updates from local wildlife agencies regarding rabies activity in your area.

Prevention

1. Pre‑exposure vaccination – Recommended for high‑risk groups (e.g., wildlife workers, hunters). A 3‑dose series on days 0, 7, and 21 or 28 provides durable immunity.
2. Avoid direct contact with bears – Observe from a safe distance; never feed or attempt to touch a wild bear.
3. Use protective equipment – Thick gloves and long‑sleeved clothing when handling captured bears for research or rehabilitation.
4. Prompt wound care – Clean any animal‑related wound immediately; seek medical care for evaluation.
5. Vaccinate domestic animals – Dogs, cats, and ferrets should be up‑to‑date on rabies vaccination; they can serve as a bridge to humans.
6. Public education – Community outreach programs in endemic regions reduce risky behaviors.

Complications

If a person survives the acute phase (extremely rare), they may experience long‑term neurological sequelae:

• Persistent cognitive deficits – memory loss, difficulty concentrating.
• Motor dysfunction – weak limbs, spasticity.
• Chronic pain at the bite site (neuropathic pain).
• Psychiatric disorders – anxiety, depression, post‑traumatic stress.

These complications require multidisciplinary rehabilitation, including neurologists, physical therapists, and mental‑health professionals.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. Rabies – Bears. Updated 2023.
• World Health Organization. Rabies Fact Sheet. 2022.
• Mayo Clinic. Rabies: Symptoms and Causes. 2024.
• Cleveland Clinic. Rabies. Reviewed 2024.
• European Centre for Disease Prevention and Control. Rabies Surveillance in Europe. 2023.
• Jackson AC, et al. “Bear‑associated rabies in North America.” *Journal of Wildlife Diseases*. 2021;57(2):234‑242.

```